Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Obesity is very common in patients with heart failure with preserved ejection fraction
(HFpEF) and it has been suggested that obesity plays an important role in the …

Accumulating evidence points to the existence of an inflammatory‐metabolic phenotype of
heart failure with a preserved ejection fraction (HFpEF), which is characterized by …

Diabetes promotes the development of both heart failure with a reduced ejection fraction
and heart failure with a preserved ejection fraction through diverse mechanisms, which are …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Heart failure (HF) is marked by distinctive changes in myocardial uptake and utilization of
energy substrates. Among the different types of HF, HF with preserved ejection fraction …

Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a
paramount treatment for patients with heart failure (HF), irrespective of underlying reduced …

Aim Different associations between epicardial adipose tissue (EAT) and cardiac function
have been suggested in patients with heart failure with preserved (HFpEF) versus reduced …